Durvalumab with platinum-based chemotherapy for the neoadjuvant/adjuvant treatment of resectable non-small-cell lung cancer

Durvalumab in combination with platinum-based chemotherapy is in clinical development for the neoadjuvant/adjuvant treatment of resectable non-small-cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. Early-stage lung cancer is typically treated with surgery to remove the tumour, followed by chemotherapy and/or radiotherapy. However, survival rates are still poor. Symptoms include a persistent cough, shortness of breath, coughing up blood, among others. Treatment with medicines prior to surgery (neoadjuvant) may provide better long-term survival prospects and reduce the risk of disease recurrence for patients with resectable NSCLC.